BC Innovations | Mar 7, 2013
Targets & Mechanisms

ALL emerges from relapse

Separate teams led by researchers from New York University and Columbia University have identified mutations in 5ʹ-nucleotidase cytosolic II that predict relapse, drug resistance and poor prognosis in acute lymphoblastic leukemia. 1,2 Inhibiting the enzyme...
BC Innovations | Feb 28, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) 5ʹ-Nucleotidase cytosolic II (NT5C2) In vitro studies suggest inhibiting NT5C2 could help treat chemotherapy-resistant ALL. In the first study, whole-exome sequencing...
Items per page:
1 - 2 of 2